Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: INTERFERON-BETA, . Treffer: 14
2019
Jensen, PEH; Warnke, C; Ingenhoven, K; Piccoli, L; Gasis, M; Hermanrud, C; Fernandez-Rodriguez, BM; Ryner, M; Kramer, D; Link, J; Ramanujam, R; Auer, M; Buck, D; Grummel, V; Bertotti, E; Fissolo, N; Oliver-Martos, B; Nytrova, P; Khalil, M; Guger, M; Rathmaier, S; Sievers-Stober, C; Lindberg, RLP; Hässler, S; Bachelet, D; Aktas, O; Donnellan, N; Lawton, A; Hemmer, B; Havrdova, EK; Kieseier, B; Hartung, HP; Comabella, M; Montalban, X; Derfuss, T; Sellebjerg, F; Dönnes, P; Pallardy, M; Spindeldreher, S; Broët, P; Deisenhammer, F; Fogdell-Hahn, A; Sorensen, PS; ABIRISK Consortium
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.
J Neuroimmunol. 2019; 326:19-27
Doi: 10.1016/j.jneuroim.2018.11.002
Web of Science
PubMed
FullText
FullText_MUG
2014
Hegen, H; Millonig, A; Bertolotto, A; Comabella, M; Giovanonni, G; Guger, M; Hoelzl, M; Khalil, M; Killestein, J; Lindberg, R; Malucchi, S; Mehling, M; Montalban, X; Polman, CH; Rudzki, D; Schautzer, F; Sellebjerg, F; Sørensen, PS; Deisenhammer, F
Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
Mult Scler. 2014; 20(5):577-587
Doi: 10.1177/1352458513503597
Web of Science
PubMed
FullText
FullText_MUG
2009
Gneiss, C; Koudouovoh-Tripp, PM; Ropele, S; Gotwald, T; Ehling, R; Lutterotti, A; Aichner, F; Ladurner, G; Eggers, C; Schautzer, F; Künz, B; Millonig, A; Aspeck, E; Reindl, M; Berger, T; Fazekas, F; Deisenhammer, F
Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study.
Mult Scler. 2009; 15(12): 1481-1488.
Doi: 10.1177/1352458509347153
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2006
Gneiss, C; Tripp, P; Ehling, R; Khalil, M; Lutterotti, A; Egg, R; Mayringer, I; Künz, B; Berger, T; Reindl, M; Deisenhammer, F
Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies.
J Neuroimmunol. 2006; 174(1-2): 174-179.
Doi: 10.1016/j.jneuroim.2006.01.017
Web of Science
PubMed
FullText
FullText_MUG
Khalil, M; Reindl, M; Lutterotti, A; Kuenz, B; Ehling, R; Gneiss, C; Lackner, P; Deisenhammer, F; Berger, T
Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: Influence of relapses and immunomodulatory treatments.
J Neuroimmunol. 2006; 174(1-2):147-156
Doi: 10.1016/j.jneuroim.2006.01.012
Web of Science
PubMed
FullText
FullText_MUG
Lutterotti, A; Kuenz, B; Gredler, V; Khalil, M; Ehling, R; Gneiss, C; Egg, R; Deisenhammer, F; Berger, T; Reindl, M
Increased serum levels of soluble CD14 indicate stable multiple sclerosis.
J Neuroimmunol. 2006; 181(1-2):145-149
Doi: 10.1016/j.jneuroim.2006.09.002
Web of Science
PubMed
FullText
FullText_MUG
Maier, K; Kuhnert, AV; Taheri, N; Sättler, MB; Storch, MK; Williams, SK; Bähr, M; Diem, R
Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study.
Am J Pathol. 2006; 169(4):1353-1364
Doi: 10.2353/ajpath.2006.060159
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2005
Neuhaus, O; Stüve, O; Archelos, JJ; Hartung, HP
Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.
J NEUROL SCI 2005 233: 173-177.
Doi: 10.1016/j.jns.2005.03.030
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Neuhaus, O; Wiendl, H; Kieseier, BC; Archelos, JJ; Hemmer, B; Stüve, O; Hartung, HP
Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro.
J Neuroimmunol. 2005; 168(1-2):128-137
Doi: 10.1016/j.jneuroim.2005.01.024
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2003
Karaghiosoff, M; Steinborn, R; Kovarik, P; Kriegshäuser, G; Baccarini, M; Donabauer, B; Reichart, U; Kolbe, T; Bogdan, C; Leanderson, T; Levy, D; Decker, T; Müller, M
Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock.
Nat Immunol. 2003; 4(5):471-477
Doi: 10.1038/ni910
Web of Science
PubMed
FullText
FullText_MUG
Niederwieser, G; Buchinger, W; Bonelli, RM; Berghold, A; Reisecker, F; Költringer, P; Archelos, JJ
Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis.
J Neurol. 2003; 250(6):672-675
Doi: 10.1007/s00415-003-1053-9
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2002
Sorensen, PS; Fazekas, F; Lee, M
Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis.
Eur J Neurol. 2002; 9(6):557-563
Doi: 10.1046%2Fj.1468-1331.2002.00501.x
Web of Science
PubMed
FullText
FullText_MUG
2001
Niederwieser, G; Bonelli, RM; Kammerhuber, F; Reisecker, F; Költringer, P
Intracerebral haemorrhage under interferon-beta therapy.
Eur J Neurol. 2001; 8(4):363-364
Doi: 10.1046%2Fj.1468-1331.2001.00227.x
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
1990
Wagner, K; Kroisel, PM; Rosenkranz, W
Molecular and cytogenetic analysis in two patients with microdeletions of 7p and Greig syndrome: hemizygosity for PGAM2 and TCRG genes.
Genomics. 1990; 8(3):487-491
Doi: 10.1016/0888-7543(90)90035-S
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar